EP Patent

EP4173639A4 — Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent

Assigned to Raqualia Pharma Inc · Expires 2024-03-13 · 2y expired

What this patent protects

Patent listed against Erivedge.

Drugs covered by this patent

Patent Metadata

Patent number
EP4173639A4
Jurisdiction
EP
Classification
—
Expires
2024-03-13
Drug substance claim
No
Drug product claim
No
Assignee
Raqualia Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.